Curriculum vitae

Date Prepared:
September 17, 2019
Name: Stephen Xavier Skapek
Office Address:
University of Texas Southwestern Medical Center
5323 Harry Hines Blvd
Dallas, Texas 75390-9063
Work Phone: 214-648-3081
Work E-Mail: Stephen.skapek@utsouthwestern.edu
Work Fax: 214-648-3122
Place of Birth: Bloomington, Illinois

Education

Year Degree
(Honors) Field of Study
(Thesis advisor for PhDs) Institution
1984 B.A. (summa cum laude) Chemistry, Latin Duke University, Durham, NC
1988 M.D. Duke University School of Medicine, Durham, NC

Postdoctoral Training

Year(s) Titles Specialty/Discipline
(Lab PI for postdoc research) Institution
1988-1989 Intern Pediatrics Wilford Hall Medical Center, San Antonio, Texas
1989-1991 Senior Resident Pediatrics Wilford Hall Medical Center, San Antonio, Texas
1991-1994 Fellow Hematology/Oncology Dana Farber Cancer Institute and Children’s Hospital, Boston, Massachusetts
1991-1994 Research Fellow Pediatrics (Research Mentor, Andrew Lassar, PhD, Department of Biological Chemistry and Molecular Pharmacology) Harvard Medical School, Boston, Massachusetts
1995-1997 Research Scientist Institute of Biotechnology (Research Mentor: Eva Lee, PhD) University of Texas Health Science Center, San Antonio, Texas

Current Licensure and Certification

Licensure
State of Tennessee (allowed to lapse 2007)
State of Illinois
State of Texas

Board and Other Certification
American Board of Pediatrics Re-certification ID#219320, October 24, 2005
American Board of Pediatrics Sub-board of
Pediatric Hematology/Oncology Certificate #1179, Re-certified: December 11, 2008

Research Interests:

1. Elucidating molecular mechanisms controlling CDKN2A expression during development and in cancer.

2. Understanding molecular and genetic mechanisms coordinating the initiation of differentiation with cell proliferation arrest in skeletal myoblasts, and determining whether the manipulation of these programs alters the biology of rhabdomyosarcoma-derived cells.

3. Studying the molecular basis by which regulated Cyclin D1 engages p53 to foster cell senescence as a tumor suppressor mechanism.

4. Defining actionable vulnerabilities in rhabdomyosarcoma and other types of childhood soft tissue sarcoma.

Honors and Awards

Year Name of Honor/Award Awarding Organization
1983 Phi Beta Kappa Duke University
1984 Summa cum laude graduate Duke University
1984 USAF Health Professions Scholarship United States Air Force
1984 Commissioned, Second Lieutenant United States Air Force
1988 Alpha Omega Alpha Duke University
1990 Pediatric Resident Research Award (Finalist) Howard Johnson
1991 Resident Physician of the Quarter Wilford Hall Medical Center
1991 Pediatric Research Resident Research Award (Runner-up) Howard Johnson
1992 USAF Achievement Medal United States Air Force
1994 Clinical Investigator Development Award (K08) NIH
1999 Medical Research Award G and P Foundation for Cancer Research
2001 Honorable Discharge (Rank: Major) United States Air Force
2004 Research Scholar Award American Cancer Society
2011 Distinguished Professorship in Pediatric Oncology Research UT Southwestern Medical Center
2013 Distinguished Chair in Pediatric Oncology Research UT Southwestern Medical Center

Faculty Academic Appointments

Year(s) Academic Title Department Academic Institution
1994-1995 Instructor Pediatrics Harvard Medical School, Boston, Massachusetts
1996-1999 Assistant Professor Pediatrics Uniformed Services University of Health Sciences, Bethesda, Maryland
1996-1999 Chief of Pediatric Oncology Pediatrics, Division of Hematology/Oncology Wilford Hall Medical Center, San Antonio, Texas
1997-1999 Assistant Professor (non-tenure, research) (non-salary) Institute of Biotechnology University of Texas Health Science Center, San Antonio, Texas
1999-2005 Assistant Member Hematology/Oncology St. Jude Children’s Research Hospital, Memphis, Tennessee
2000-2006 Assistant Professor Pediatrics University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee
2003-2007 Assistant Professor Ophthalmology University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee
2005-2007 Associate Member Hematology/Oncology St. Jude Children’s Research Hospital, Memphis, Tennessee
2006-2007 Associate Professor Pediatrics University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee
2007-2011 Associate Professor Pediatrics, Section of Hematology/Oncology and Stem Cell Transplantation University of Chicago, Chicago, Illinois
2011-present Professor (with tenure) Pediatrics, Division of Hematology/Oncology and Harold C. Simmons Comprehensive Cancer Center University of Texas Southwestern Medical Center, Dallas, Texas

Appointments at Hospitals/Affiliated Institutions

Past
Year(s) Position Title Department/Division Institution
1994-1995 Assistant in Medicine Hematology/Oncology Children’s Hospital, Boston, Massachusetts
1995-1999 Staff Physician Division of Hematology/Oncology, Department of Pediatrics Wilford Hall Medical Center, San Antonio, Texas

1999-2007 Attending Physician Hematology/Oncology St. Jude Children’s Research Hospital, Memphis, Tennessee
2007-2011 Attending Physician Pediatrics, Section of Hematology/Oncology and Stem Cell Transplantation The University of Chicago Comer Children’s Hospital, Chicago, Illinois

Current
Year(s) Position Title Department/Division Institution
2011 – present Attending Physician Hematology/Oncology Children’s Medical Center, Dallas, Texas
2011 – present Attending Physician Pediatric Hematology/Oncology Parkland Hospital, Dallas, Texas
2011 – present Attending Physician Pediatric Hematology/Oncology Children’s Medical Center, Plano, Texas
2015 – present Attending Physician Hematology/Oncology Clements University Hospital, Dallas, Texas

Other Professional Positions

Year(s) Position Title Institution
1984 Commissioned as 2nd Lieutenant as part of Health Professions Scholarship Program United States Air Force Reserve
July 1988-June 1991 United States Air Force Active Duty Wilford Hall USAF Medical Center, Lackland AFB, Texas
October 1995-March 1999 United States Air Force Active Duty Wilford Hall USAF Medical Center, Lackland AFB, Texas

Major Administrative/Leadership Positions

Year(s) Position Title Institution
1992-1995 Clinical Protocol Chair: Vinblastine and methotrexate for children with aggressive fibromatosis (Desmoid Tumor) Dana Farber Cancer Institute, Boston, Massachusetts
1993-1995 Clinical Protocol Chair: Asparaginase-associated lipid abnormalities in children with acute leukemia Dana Farber Cancer Institute, Boston, Massachusetts
1996-1999 Principal Investigator, Pediatric Oncology Group Wilford Hall Medical Center, San Antonio, Texas
1996-1999 Chief of Pediatric Oncology Wilford Hall Medical Center, San Antonio, Texas
1997 – 2000 Study Chair: Vinblastine and methotrexate
In children with desmoid tumor (aggressive
fibromatosis) which is recurrent or not amenable
to surgical resection or irradiation (POG 9650 study) Pediatric Oncology Group
2004 – 2009 Study Chair: A phase II study of sulindac and tamoxifen in patients with desmoid tumor that is recurrent or not amenable to standard therapy (ARST0321 study) Children’s Oncology Group
2007–2010 Director of Oncology, Department of Pediatrics, Section of Hematology/Oncology and Stem Cell Transplantation, The University of Chicago University of Chicago, Chicago, Illinois
2007–2010 Chair, Clinical Care Committee, Section of Hematology/Oncology/Stem Cell Transplantation, Department of Pediatrics University of Chicago, Chicago, Illinois
2007 – present Study Chair: A COG soft tissue sarcoma biology and banking study (D9902 study) Children’s Oncology Group
2010–2011 Fellowship Program Director, Pediatric Hematology/Oncology, Department of Pediatrics University of Chicago, Chicago, Illinois
2011 – present Chief, Division of Hematology/Oncology, Department of Pediatrics UT Southwestern Medical Center, Dallas, Texas
2011 – present Medical Director, Pauline Allen Gill Center for Cancer and Blood Disorders Children’s Medical Center, Dallas, Texas
2013 Pediatric Oncology Track Leader, Cancer Education Committee American Society of Clinical Oncology
2013-present Co-Leader, Cancer and Development Scientific Program, Harold C. Simmons Comprehensive Cancer Center UT Southwestern Medical Center, Dallas, Texas
2014-present Member, Scientific Council, Children’s Oncology Group Children’s Oncology Group
2015-2017 Vice-Chair, Advisory Committee on Childhood Cancer Cancer Prevention and Research Institute of Texas
2018-present Chair, Advisory Committee on Childhood Cancer Cancer Prevention and Research Institute of Texas

Committee Service (Member, unless noted otherwise)

Year(s) Name of Committee Institution/Organization
UTSW
2013 – present Promotion and Tenure Committee UT Southwestern Medical Center
2015 Steering Committee member and Workgroup Co-Chair, Pediatric Strategic Planning Workgroup UT Southwestern Medical Center
2016 – present Pediatric Group Practice Committee UT Southwestern Medical Center

Hospital
1999-2001 Infection Control Committee St. Jude Children’s Research Hospital
2000-2002 Metabolic Support Services Committee St. Jude Children’s Research Hospital
1999 Institutional Review Board sub-committee on Assent St. Jude Children’s Research Hospital
2000 Education Program Committee St. Jude Children’s Research Hospital
2003-2007 Ethics Committee St. Jude Children’s Research Hospital
2010-2011 Residency Recruitment Committee The University of Chicago Comer Children’s Hospital

State/Regional
2014 – present Advisory Committee on Childhood Cancer Cancer Prevention and Research Institute of Texas
2015 – 2017 Vice Chair, Advisory Committee on Childhood Cancer Cancer Prevention and Research Institute of Texas
2018 - present Chair, Advisory Committee on Childhood Cancer Cancer Prevention and Research Institute of Texas

National/International
2009 – present Vice Chair – Biology, Soft Tissue Sarcoma Committee Children’s Oncology Group
2009 – present Steering Committee, Soft Tissue Sarcoma Committee Children’s Oncology Group
2010 – present Scientific Advisory Board,
Make Some Noise Foundation: Cure Kids Cancer Foundation
2010 – 2013 Cancer Education Committee, Pediatric Cancer track American Society of Clinical Oncology
2011 – present Study Committee Member: A feasibility study of either sorafenib or pazopanib in combination with ifosfamide and doxorubicin +/- radiotherapy in patients with newly diagnosed intermediate-or high-risk non-rhabdomyosarcoma soft tissue sarcoma (ARST1221 study) Children’s Oncology Group
2014 – present Executive Committee Children’s Oncology Group
2015 – 2018 Alternate Member, National Clinical Trials Network Core Correlative Sciences Committee Cancer Therapy Evaluation Program, National Cancer Institute
2018 - present Co-Chair, National Clinical Trials Network Core Correlative Sciences Committee - B Cancer Therapy Evaluation Program, National Cancer Institute

Professional Societies

Dates Society Name
1997 – present Pediatric Oncology Group/Children’s Oncology Group, Full Member
Soft Tissue Sarcoma sub-committee member
1999 – 2000 Intergroup Rhabdomyosarcoma Study Group, Associate Member
2006 – present Association for Research in Vision and Ophthalmology, Member
2008 – present American Society of Pediatric Hematology/Oncology, Member
2008 – present American Association for Cancer Research, Member

Editorial Activities

Year(s) Journal Name
Editorial Board
2011-2015 Journal of Clinical Oncology

Ad Hoc Reviewer
American Journal of Pathology
Cancer
Cell Reports
Clinical Cancer Research
Journal of Pediatric Hematology/Oncology
Journal of Cell Biology
Molecular and Cellular Biology
Pediatric Blood and Cancer
Pediatric Hematology and Oncology
Pediatrics
Cancer Research UK (research grant proposals)

Grant Support

Present Imaging and computational tools for risk stratification in children with osteosarcoma
Cancer Prevention and Research Institute of Texas Individual Investigator Research Award (RP150164)(Leavey)
(Collaborator) (03/01/2015 – 02/28/19)(NCE)

Molecularly targeted therapy for soft tissue sarcoma in Texas
Cancer Prevention and Research Institute of Texas Multi-Investigator Research Award (RP120685) (Skapek)
(Overall PI and Administrative Core PI) (09/01/2012 – 8/31/19)(NCE)

High throughput screening for sarcoma cell proliferation and survival factors
Cancer Prevention and Research Institute of Texas Multi-Investigator Research Award (RP120685) (Skapek)
(Project 2 PI) (09/01/2012 – 08/31/19)(NCE)

Children's Oncology Group Award / Clinical Rider
National Childhood Cancer Foundation U10 CA180886 (Adamson)
(Vice Chair-Soft Tissue Sarcoma committee) (03/01/10 – 02/28/18)

Physician Scientist Oncology Training Program
National Cancer Institute T32 CA136515 (Skapek)
(PI) (09/01/09 – 8/31/20) (NCE)

University of Texas Southwestern Harold C. Simmons Comprehensive Cancer
Center Support Grant
National Cancer Institute P30 CA142543 (Cobb)
(Co-Leader, Development and Cancer Program) (08/03/10 – 7/31/20)

Developmental and HyperActive RAS Tumor SPORE
National Institutes of Health/NCI U54 CA196519 (Clapp/Shannon)
Project 2 Co-Leader: Targeted therapies for malignant peripheral nerve sheath tumor
(07/01/15 – 06/30/20)

Rhabdomyosarcoma vulnerabilities: Prioritizing and extending to the clinic
Cancer Prevention and Research Institute of Texas Individual Investigator Research Award for Cancer in Children and Adolescents (RP180319) (Skapek)
(PI) (03/01/2018 – 02/28/22)

Pending
Tgfβ2 controls p19Arf during eye development
National Institutes of Health (NEI) 2 R01 EY019942 (Skapek)
(PI/MPI)(9/21/2019 – 8/31/2024)

Restoring CDKN2A and CDKN2B tumor suppressors in rhabdomyosarcoma
National Institutes of Health (NCI) R01 CA249208 (Skapek)
(PI)(04/01/2020 – 3/31/2025)

Restoring CDKN2A and CDKN2B tumor suppressors in rhabdomyosarcoma
Cancer Prevention and Research Institute of Texas (IIRACCA) RP200338 (Skapek)
(PI)(04/01/2020 – 3/31/2025)

New tools to study human CDKN2A and CDKN2B in development and disease
National Institutes of Health (NICHD) R21 HD102002 (Skapek)
(PI)(04/01/2020 – 3/31/2022)

Somatic aberrations at chromosome 9p21 as a driver of childhood disease
National Institutes of Health (NICHD) R21 HD101860 (Xu/Skapek)
(PI/MPI)(04/01/2020 – 3/31/2022)

Past
Cell cycle-dependent regulation of myogenesis
National Institute of Child Health and Human Development
(NIH Clinical Investigator Development Award-K08)(Skapek)
(PI)(12/1/94 - 11/30/99)

Regulation of G1 cyclins in Dystrophin-deficient myocytes
Muscular Dystrophy Association (Skapek)
(7/1/97 – 6/30/00)

Analysis of RB-associated transcriptional repressor in leukemia
G and P Charitable Foundation for Cancer Research (Medical Research Award) (Skapek)
(PI) (10/29/1999–10/28/2002)

ARF controls vascular regression during eye development
National Institutes of Health (NEI) (R01 EY014368)(Skapek)
(PI)(8/01/2003–7/31/2008)

The Arf tumor suppressor as a regulator of vascular regression
American Cancer Society (RSG# 04-036-01-DDC) (Skapek)
(PI) (01/01/2004–12/31/2007)

Translation of predictive cancer biomarkers into clinical practice
National Institutes of Health (NCI) (1 RC2 CA148216) (Skapek/Triche)
(PI/MPI)(09/29/2009 – 08/31/2011)

De-regulated mTOR in desmoid-type fibromatosis: Identification and validation of a new therapeutic target
Desmoid Tumor Research Foundation (Skapek)
(PI)(02/01/2010-01/31/2012)

Histologic criteria and surrogate markers alveolar Rhabdomyosarcoma
St. Baldrick’s Foundation (Rudzinski)
(collaborator) (07/01/2010-06/30/2011)

Molecular targeting in non-rhabdomyosarcoma soft tissue sarcoma
St. Baldrick’s Foundation Consortium Award (Skapek)
(PI)(07/01/2011 – 08/31/2014)

Prognostic Significance of Fusion Status in Low and High Risk Rhabdomyosarcoma
St. Baldrick’s Foundation (PI: Rudzinski)
(Co-PI) (7/01/12 – 6/30/14)

Targeting the SRC oncogene to promote muscle differentiation as a new therapy for
Rhabdomyosarcoma
Hyundai Hope on Wheels Award 56745TX (Zheng)
(Co-PI) (9/1/12 – 8/31/14)

Tgfβ2 controls p19Arf during eye development
National Institutes of Health (NEI) 2 R01 EY019942 (Skapek)
(PI)(12/01/2009 – 3/31/2019)

COG NCTN Integrated Translational Science Center for Solid Tumors
National Institutes of Health (NCI) 1 U10 CA180884 (Skapek/Adamson)
(PI/MPI) (05/15/2014 – 02/28/2019)

Teaching Activities

Formal Teaching

10/24/02 Clinical Correlation: Cell Cycle. Molecular Basis of Disease (1st year medical
school course at University of Tennessee School of Medicine). Course Director: Arthur Geller.

10/21/03 Clinical Correlation: Cell Cycle. Molecular Basis of Disease (1st year medical school
course at University of Tennessee School of Medicine). Course Director: Arthur Geller.

04/28/04 Regulation of Skeletal Muscle Differentiation. Cell Biology (Bioc 826) (Lecture for 1st
year graduate students at the University of Tennessee Health Science Center). Course Director: R. K. Rao.

07/14/04 Introduction to Pediatric Cancer Biology. Part of Pediatric Resident Education Series. St.
Jude Children’s Research Hospital.

11/09/04 Clinical Correlation: Cell Cycle. Molecular Basis of Disease (1st year medical school
course at University of Tennessee School of Medicine). Course Director: Arthur Geller.

01/31/05 Regulation of Skeletal Muscle Differentiation. Cell and Molecular Biology (IP 843)
(Lecture for 1st year graduate students at the University of Tennessee Health Science Center). Course Director: R. K. Rao.

02/23/05 Introduction to Pediatric Cancer Biology. Part of Pediatric Resident Education Series.
St. Jude Children’s Research Hospital.
08/03/05 Introduction to Pediatric Cancer Biology. Part of Pediatric Resident Education Series. St. Jude Children’s Research Hospital.

10/20/05 Clinical Correlation: Cell Cycle. Molecular Basis of Disease (1st year medical school course at University of Tennessee School of Medicine). Course Director: Arthur Geller.

01/31/06 Regulation of Skeletal Muscle Differentiation. Cell and Molecular Biology (IP 843)
(Lecture for 1st year graduate students at the University of Tennessee Health Science Center). Course Director: R. K. Rao.

10/26/06 Clinical Correlation: Cell Cycle. Molecular Basis of Disease (1st year medical school
course at University of Tennessee School of Medicine). Course Director: Arthur Geller.

12/04/06 Biology of Angiogenesis. Molecular Basis of Cancer course (IP 940) (Seminar for 2nd year
graduate students at the University of Tennessee Health Science Center). Course Director: Parker Suttle. (2 lectures)

01/31/07 Regulation of Skeletal Muscle Differentiation. Cell and Molecular Biology (IP 843)
(Lecture for 1st year graduate students at the University of Tennessee Health Science Center). Course Director: R. K. Rao.

10/01/11- Full member, Genetics, Development, and Disease, and Cancer Biology graduate programs University of Texas Southwestern Medical Center

Mentoring

Professional Oncology Education program at St. Jude Children’s Research Hospital:
Dongngan Truong, Dartmouth College, June - September 2001.
Denise Fraga, University of Notre Dame, June - August 2001; June - August 2002.
Ashleigh Frith, Christian Brothers University, May - August 2003.
Tiffany Chin, Covenant College, May - August 2006

Postdoctoral Fellows:
Nikita Warner, PhD, Postdoctoral Research Associate, July 1999 – September 2001.
Next position: Scientist, Cato Research, Ltd. San Diego, CA.

Chan Hon Chui, MD, Surgery Fellow, July 1999 – June 2000.
Next position: Department of Surgery, National University Hospital, Republic of Singapore
Kenneth Gow, MD, Surgery Fellow, July 2000 – June 2001.
Next position: Department of Surgery, Emory University, Atlanta, GA.

Ricardo Silva, PhD, Research Associate, April 2004 – August 2005.
Next position: Instituto Nacional do Cancer, Rio de Janeiro, Brazil

Raya Saab, MD, Clinical Fellow, Hematology/Oncology, July 2004 – 2007.
Next position: Assistant Professor, Pediatric Hematology/Oncology, American University of Beirut, Beirut, Lebanon

Natalie Anderson, PhD, Postdoctoral Research Associate, December 2005 – 2007.
Next position: Instructor/Faculty in the Ophthalmology Department at the Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN

Dipti Dighe, MD Clinical Fellow, Pediatric Hematology/Oncology, University of Chicago,
July 2008 – 2010
Next position: Attending Physician, John H. Stroger, Jr. Hospital, Chicago, IL

Anna Zelivianskia, Undergraduate student research Honors Thesis program, University of
Chicago, 2008 – 2011

Patricia Chu, Undergraduate student research Honors Thesis program, University of Chicago,
2008 – 2011

Ryan Widau, PhD, Postdoctoral Research Scholar, University of Chicago, 2010 – 2011

Jie Mei, PhD, Postdoctoral Research Associate, University of Texas Southwestern Medical Center, 2012 – 2013

Lin Xu, PhD, Postdoctoral Research Associate, University of Texas Southwestern Medical Center, 2013 – present

Yen-Ting Liu, PhD, Postdoctoral Research Associate, University of Texas Southwestern Medical Center, 2014 – present

Erin Butler, MD, Clinical Fellow, Hematology/Oncology, University of Texas Southwestern Medical Center, 2015 – present

Graduate Students:
Fazle Chowdhury. PhD-track graduate student in the Integrated Program in Biomedical Sciences (Cancer
Biology and Developmental track) at the University of Tennessee Health Science Center. July 2006 – 7; transferred to MS program.

Daniel Taylor. MS-track graduate student in the Integrated Program in Biomedical Sciences at the
University of Tennessee Health Science Center. July 2007 – 2008. Thesis defense: June 2008

Steve Kregel. PhD candidate, Cancer Biology, The University of Chicago. Spring 2010 rotation.

Nida Iqbal. PhD candidate, Genetics and Development, University of Texas Southwestern Medical Center, 2012 – 2015 (successfully completed degree requirements)

Caroline Sung. PhD candidate, Genetics and Development, University of Texas Southwestern Medical Center, 2012 – 2015 (successfully completed degree requirements)

Jared Hooks. PhD candidate, Cancer Biology, University of Texas Southwestern Medical Center, 2014 – 2016) (successfully defended dissertation)

Invited Lectures

1. Medical overview of pediatric oncology. Presented at Dana-Farber Cancer Institute School Teacher’s Workshop. Boston, Massachusetts, April 18, 1992.

2. Medical overview of pediatric oncology. Presented at Dana-Farber Cancer Institute School Teacher’s Workshop. Boston, Massachusetts, November 17, 1994.

3. The molecular basis for coordinating cell cycle arrest and skeletal muscle differentiation: possible implications for childhood cancer. Presented at Workshop for Connor Moran Children’s Cancer Foundation. Palm Beach, Florida, February 23, 1995.

4. The coordinated regulation of skeletal muscle differentiation and cell cycle arrest. Presented at Institute for Biotechnology, University of Texas Health Science Center at San Antonio. San Antonio, Texas, March 17, 1995.

5. Cyclin D1-dependent inhibition of skeletal muscle differentiation. Presented at Wilford Hall USAF Medical Center. San Antonio, Texas, March 17, 1995.

6. Angiogenesis inhibition as a novel therapy for children with brain tumors. Presented at American Cancer Society’s 37th Annual Science Writer’s Seminar. New Orleans, Louisiana, March 27, 1995.

7. Review of Pediatric Oncology Topics: Acute lymphoblastic leukemia and anti-angiogenesis therapy for childhood brain tumors. Carney Hospital Pediatric Grand Rounds. Dorchester, Massachusetts, June 23, 1995.

8. Overview of Childhood Brain Tumors. Children’s Hospital Pediatric Oncology Grand Rounds. Boston, Massachusetts, August 17, 1995.

9. Cyclin D1-mediated inhibition of skeletal muscle differentiation involved RB-dependent and RB-independent mechanisms. Short talk presented at meeting on The Cell Cycle. Cold Spring Harbor Laboratory, New York, May 19, 1996.

10. Pathogenesis and treatment of desmoid tumor in pediatric patients. Pediatric Oncology Teaching Conference. Santa Rosa Children’s Hospital. San Antonio, Texas, November 5, 1997.

11. Cell cycle-dependent regulation of gene expression during differentiation of skeletal muscle cells. Seminar presented at St. Jude Children’s Research Hospital. Memphis, Tennessee, January 8, 1998.

12 Effects of ectopic expression of cyclin D1 in the mouse retina and pineal gland. Seminar presented at Brain Tumor Team Meeting. St. Jude Children’s Research Hospital. Memphis, Tennessee, October 17, 1999.

13. The RB gene pathway and the coordination of cell cycle arrest and differentiation – implications for development and cancer. Memorial Sloan-Kettering Cancer Center Pediatric Grand Rounds. New York, New York, April 5, 2001.

14. Persistent expression of Cyclin D1 disrupts normal photoreceptor differentiation and retina development. Short talk presented at 2001 Gordon Research Conference on Cancer: Mechanisms and Models. Newport, RI, August 2, 2001.

15. Arf controls vascular regression in the developing eye. Short talk presented at the Cancer Genetics and Tumor Suppressor Genes meeting. Cold Spring Harbor, NY, August 14, 2002.

16. Muscle differentiation and rhabdomyosarcoma. Sarcomas: Bench to Bedside. Cancer Center Symposium, St. Jude Children’s Research Hospital, Memphis, Tennessee, November 1, 2002.

17. A new role for the ARF tumor suppressor during eye development. Research Seminar, University of Texas Health Science Center at San Antonio, Texas, May 1, 2003.

18. Skeletal muscle differentiation and rhabdomyosarcoma – new insights into the disease? Pediatric Grand Rounds, University of Texas Health Science Center at San Antonio, Texas, May 2, 2003.

19. Cyclin D1 and p19Arf: Regulators of differentiation and vascular involution in mouse models of childhood cancer and eye disease. Seminar presented to the Department of Pediatric Hematology/Oncology, The Children’s Hospital at the Cleveland Clinic. Cleveland, Ohio. August 6, 2003.

20. The Arf tumor suppressor as a regulator of vascular regression. Seminar presented to the faculty of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, June 23, 2004.

21. The Arf tumor suppressor is required for vascular regression during eye development. Short talk presented at 2004 Gordon Research Conference on Cancer: Models and Mechanisms. Newport, RI, August 3, 2004.

22. New functions for the p19Arf tumor suppressor. Seminar presented to the Division of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, December 14, 2004.

23. Arf tumor suppressor gene function in vascular developmental biology. Seminar presented to the Department of Pharmacology, University of Tennessee Health Science Center, Memphis, TN, January 5, 2005.

24. Can a “Developmental Perspective” provide new insight into cancer biology? Faculty Promotion Seminar. Presented at St. Jude Children’s Research Hospital, Memphis, TN, May 25, 2005.

25. A role for the Arf tumor suppressor in development. Biomedical Research Forum Lecture, St. Jude Children’s Research Hospital, Memphis, TN, June 13, 2005.

26. Unexpected functions for the Arf tumor suppressor in eye development. Seminar presented at Dartmouth-Hitchcock Medical Center, Lebanon, NH, June 14, 2005.

27. Non-rhabdomyosarcoma soft tissue sarcoma. Pediatric Surgical Oncology Review Course for Fellows. St. Jude Children’s Research Hospital, Memphis, TN, March 4, 2006.

28. Diagnosis and management of soft tissue sarcoma in children. Grand Rounds presentation at the University of Texas Health Science Center, San Antonio, TX, June 2, 2006.

29. Developmental functions for the Arf tumor suppressor gene. Seminar presented in the Department of Pediatrics, Mount Sinai School of Medicine, New York, NY, June 13, 2006.

30. Cancer biology insight from developmental studies. Seminar presented in the Department of Pediatrics, Oregon Health and Science University, Portland, OR, November 14, 2006.

31. What can studies in development teach us about childhood cancer biology? Seminar presented at the Pediatric Oncology Grand Rounds, Memorial Sloan Kettering Cancer Center, New York, NY, January 18, 2007.

32. Chemotherapy for Aggressive Fibromatosis (Desmoid Tumor). Seminar presented at the Musculoskeletal Tumor Society Specialty Day program at the American Academy of Orthopedic Surgeons meeting, San Diego, CA, February 17, 2007.

33. Oncogene-induced senescence blocks Cyclin D1-driven pineoblastoma in a transgenic mouse model. Research work from Skapek laboratory presented by R. Saab, postdoctoral fellow. Mechanisms and Models of Cancer Meeting, The Salk Institute, La Jolla, CA, August 10, 2007.

34. Rhabdomyosarcoma: how can we cure the children with highest-risk disease? Pediatric Grand Rounds, MD Anderson Cancer Center, Houston, TX, March 17, 2008.

35. Management of fever and neutropenia in childhood cancer patients. Pediatric Grand Rounds, Rush University Medical Center, Chicago, IL, July 22, 2008.

36. The Arf tumor suppressor: at the intersection of cancer and developmental biology? Seminar presented to the Committee on Developmental Biology, University of Chicago, Chicago, IL, September 16, 2008.

37. The Arf tumor suppressor: at the intersection of cancer and developmental biology? Seminar presented at the University of Chicago Biomedical Sciences Symposium, April 24 – 25, 2009.

38. Rhabdomyosarcoma: How can we cure those children with the highest risk disease? Pediatric Hematology-Oncology Grand Rounds presented at the University of Texas Southwestern Medical School, January 26, 2010.

39. Potential actionable mutations: Incorporating testing into NRSTS clinical trial. International Symposium on Biology and Treatment of Pediatric Soft Tissue Sarcomas, Padova, IT, December 6, 2011.

40. The Arf tumor suppressor at the intersection of tumor suppression and development. Seminar presented at The Research Institute, Nationwide Children’s Hospital, July 25, 2013.

41. The Arf tumor suppressor: At the intersection of cancer and development. Seminar presented at the University of Arizona Cancer Center, October 12, 2016.

42. Identifying Oncogenic Drivers in Rhabdomyosarcoma. Research seminar presented at Duke University Cancer Institute, March 23, 2017

Scientific Peer Review

04/18/04–04/20/04 Scientist Reviewer – FY 2004 Department of Defense Prostate Cancer Research Program. Molecular Biology and Genetics #1 Peer Review Panel.

03/04/05 Scientist Reviewer – FY2004 USAMRMC/CDMRP Breast Cancer Research Program Concept Awards. Molecular Biology and Genetics #1 Peer Review Panel.

04/10/05–04/12/05 Scientist Reviewer – FY 2005 Department of Defense Prostate Cancer Research Program. Molecular Biology and Genetics #1 Peer Review Panel.

10/24/05 Scientist Reviewer – Tumor Cell Biology Study Section, Center for Scientific Review/National Institutes of Health

01/11/06–01/12/06 Scientist Reviewer – Development, Differentiation and Cancer Peer Review Committee (ad hoc). American Cancer Society.

03/27/2006 Scientist Reviewer – FY2005 USAMRMC/CDMRP Breast Cancer Research Program Concept Awards. Molecular Biology and Genetics #1 Peer Review Panel.

06/20/06–06/21/06 Scientist Reviewer – FY 2006 Department of Defense Prostate Cancer Research Program. Molecular Biology and Genetics #1 Peer Review Panel.

06/28/06–06/29/06 Scientist Reviewer – Development, Differentiation and Cancer Peer Review Committee (ad hoc). American Cancer Society.

01/01/07–06/01/2011 Member, Peer Review Committee on Development, Differentiation and Cancer. American Cancer Society.

08/19/07–08/21/07 Scientist Reviewer – FY2007 USAMRMC/CDMRP Breast Cancer Research Program. Molecular Biology and Genetics #1 Peer Review Panel.

03/05/08 Scientist Reviewer – FY2005 USAMRMC/CDMRP Breast Cancer Research Program Concept Awards. Molecular Biology and Genetics #1 Peer Review Panel.

09/08/08–09/09/08 Scientist Reviewer – FY2009 USAMRMC/CDMRP Breast Cancer Research Program. Molecular Biology and Genetics #1 Peer Review Panel.

06/08/09–06/09/09 Scientist Reviewer – FY2009 USAMRMC/CDMRP Breast Cancer Research Program. Molecular Biology and Genetics #1 Peer Review Panel.

04/28/16 Scientist Reviewer, QuadW Foundation – AACR Fellowship for Clinical/Translational Sarcoma Research Scientific Review Committee.

02/09/17–02/10/17 Scientist Reviewer, NCI SPORE Review Panel, Center for Scientific Review/National Institutes of Health.

10/19/17–10/20/17 Scientist Reviewer, NCI SPORE Review Panel, Center for Scientific Review/National Institutes of Health.

02/23/18 Scientist Reviewer, QuadW Foundation – AACR Fellowship for Clinical/Translational Sarcoma Research Scientific Review Committee.

1/29/19–1/30/19 Scientist Reviewer, NCI SPORE Review Panel, Center for Scientific Review/National Institutes of Health.

Bibliography

Original Research Articles

1. Skapek SX, Colvin OM, Griffith OW, Elion GB, Bigner DD, Friedman HS. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Cancer Res 48:2764-2767, 1988.

2. Skapek SX, Colvin OM, Griffith OW, Groothuis DR, Colapinto EV, Lee Y, Hilton J, Elion GB, Bigner DD, Friedman HS. Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts. Biochem Pharm 37:4313-4317, 1988.

3. Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold, SC, Jacobsen PF, Muhlbaier LH, Bigner DD. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48:4189-4195, 1988.

4. He X, Skapek SX, Wikstrand CJ, Friedman HS, Trojanowski JQ, Kemshead JT, Coakham HB, Bigner SH, Bigner DD. Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. J Neuropathol Exp Neurol 48:48-68, 1989.

5. Friedman HS, Skapek SX, Colvin OM, Elion GB, Blum MR, Savina PM, Hilton J, Schold SC, Kurtzberg J, Bigner DD. Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. Cancer Res 48:5397-5402, 1989.

6. Skapek SX, VanDellen AF, McMahon DP, Postels DG, Griffith OW, Bigner DD, Friedman HS. Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. Cancer Chemother Pharmacol 28:15-21, 1991.

7. Skapek SX, Jones WS, Hoffman KM, Kuskie MR. Sinusitis and bacteremia caused by Flavobacterium meningosepticum in a 16 year old with Shwachman Diamond Syndrome. Pediatr Infect Dis J 11:411-413, 1992.

8. Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267:1022-1024, 1995.

9. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB. Terminal cell cycle arrest of skeletal muscle correlates with induction of p21 by MyoD. Science 267:1018-1021, 1995.

10. Skapek SX, Rhee J, Kim PS, Novitch BG, Lassar AB. Cyclin-mediated inhibition to MyoD function via pRB-dependent and pRB-independent mechanisms. Mol Cell Biol 16:7043-7053, 1996.

11. Parsons SK, Skapek SX, Neufeld EJ, Kuhlman C, Young ML, Donnelly M, Brunzell JD, Otvos JD, Sallan SE, Rifai N. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 89:1886-1895, 1997.

12. Skapek SX, Hawk BJ, Hoffer FA, Dahl GV, Granowetter L, Gebhart MC, Ferguson WS, Grier HE. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol 16:3021-3027, 1998.

13. Skapek SX, Jansen D, Wei TF, McDermott T, Huang W, Olson EN, and Lee EYHP. Cloning and characterization of a novel KRAB family transcriptional repressor that interacts with the retinoblastoma gene product, RB. J Biol Chem 275: 7212-7223; 2000.

14. Lin SCL, Skapek SX, Papermaster DS, Hankin M, and Lee EYHP. The proliferative and apoptotic activities of E2F1 in the mouse retina. Oncogene 20: 7073-7084, 2001.

15. Skapek SX, Lin SCL, Jablonski M, McKeller R, Hu NP, and Lee EYHP. Persistent expression of cyclin D1 disrupts normal photoreceptor differentiation and retina development. Oncogene 20: 6742-6751, 2001.

16. McKeller RN, Fowler JL, Cunningham JJ, Warner NW, Smeyne RJ, Zindy F, and Skapek SX. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proceedings of the National Academy of Science 99: 3848-3853, 2002.

17. McCarville MB, Spunt SL, Skapek SX, and Pappo AS. Synovial sarcoma in pediatric patients. American Journal of Roentgenology 179: 797-801; 2002.

18. Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, and Sherr CJ. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proceedings of the National Academy of Science 100: 15930 - 15935, 2003.

19. Martin AC, Thornton JD, Liu J, Wang XF, Zuo J, Jablonski MM, Chaum E, Zindy F, and Skapek SX. Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the Arf tumor suppressor gene. Investigative Ophthalmology and Visual Sciences 45: 3387 – 3396, 2004.

20. Silva RLA, Martin AC, Thornton JD, Rehg JE, Berwistle D, Zindy F, and Skapek SX. Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing eye. The EMBO Journal 24: 2803-2814; 2005.

21. Thornton JD, Silva RLA, Martin AC, and Skapek SX. The Arf tumor suppressor regulates Platelet-derived growth factor receptor  signaling: a new view through the eyes of Arf -/- mice. Cell Cycle 4: 1316-1319; 2005.

22. Saab RH, Bill JL, Miceli A, Anderson CM, Khoury J, Fry DW, Navid F, Houghton PJ, and Skapek SX. Pharmacological inhibition of cyclin-dependent kinase 4 arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Molecular Cancer Therapeutics 5: 1299-1308; 2006.

23. Ganti R, Skapek SX, Zhang J, Fuller CE, Wu J, Billups C, Breitfeld PP, Dalton JD, Meyer WH, and Khoury JD. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Modern Pathology 19: 1213-1220; 2006.

24. Skapek SX, Pan Y-R, and Lee, EYHP. Regulation of cell lineage specification by the retinoblastoma tumor suppressor. Oncogene 25: 5268-76, 2006.

25. Gaillard P, Krasin MJ, Laningham FH, Hoffer FA, Davidoff AM, Spunt SL, Smiley L, and Skapek SX. Hematometrocolpos in an adolescent female treated for pelvic Ewing sarcoma. Pediatric Blood and Cancer 2006 Mar 20; [Epub ahead of print] PMID: 16550535.

26. Goodin GS, McCarville MB, Thibodeau SN, Skapek SX, Khoury JD, and Spunt SL. Prolactinoma as the first manifestation of Gardner’s Syndrome. Pediatric Blood and Cancer 2006 Jul 21; [Epub ahead of print] PMID: 16862550.

27. Thornton JD, Swanson D, Mary MN, Pei D, Martin AC, Pounds S, Goldowitz D, and Skapek SX. Persistent hyperplastic primary vitreous due to somatic mosaic deletion of the Arf tumor suppressor. Investigative Ophthalmology and Visual Sciences 48: 491-499, 2007.

28. Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, Hoffer FA, Speights R, Gebhardt MC, Dahl GV, and Grier HE. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group phase II trial. J Clinical Oncology 25: 501-506, 2007.

29. Dickson PV, Hamner JB, Streck CJ, Ng CY, McCarville MB, Calabrese C, Gilbertson RJ, Stewart CF, Wilson CM, Gaber MW, Pfeffer LM, Skapek SX, Nathwani AC, and Davidoff AM. Continuous delivery of IFN-beta promotes sustained maturation of intratumoral vasculature. Molecular Cancer Research 5: 531-542; 2007.

30. McCarville MB, Hoffer FA, Adelman CS, Khoury JD, Li C, and Skapek SX. Magnetic resonance imaging and biological behavior of desmoid tumor in children. American J Roentgenology 189:633-40; 2007

31. Saab R, Rodriguez-Galindo C, Matmati K, Rehg J, Baumer SH, Khoury JD, Billups C, Neale G, Helton KJ, and Skapek SX. p18Ink4c and p53 act as tumor suppressors in Cyclin D1-driven primitive neuroectodermal tumor. Cancer Research 9:440-8, 2009

32. Anderson-Freeman NE, Zheng Y, McCalla-Martin AC, Zheng Y, Treanor LM, Zhao YD, Garfin PM, He TC, Mary MN, Thornton JD, Anderson C, Gibbons M, Saab R, Baumer SH, Cunningham J, and Skapek SX. Expression of the Arf tumor suppressor gene is controlled by Tgf2 during development. Development 136: 2081-2089, 2009.

33. Zheng Y, Zhao YD, Gibbons M, Abramova T, Chu PY, Ash JD, Cunningham JC, and Skapek SX. Tgf signaling directly induces Arf promoter remodeling by a mechanism involving Smads 2/3 and p38 MAPK. J Biological Chemistry 285: 35654-64, 2010.

34. Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Stephen X. Skapek SX, Hayes-Jordan AA, Donaldson SS, Brown K, Triche TJ, Meyer WH, Hawkins DS. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clinical Oncology 29: 1304-1311; 2011

35. Al-Tahan A, Sarkis O, Harajly M, Baghdadi OK, Zibara K, Boulos F, Dighe D, Kregel S, Bazarbachi A, El-Sabban M, Skapek SX, Saab R. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma. Pediatric Blood and Cancer 58: 877-884; 2012

36. Spunt SL, Vargas SQ, Coffin CM, Skapek SX, Parham DM, Darling J, Hawkins DS, Keller C. The clinical, research, and social value of autopsy after any cancer death: A perspective from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Cancer 118: 3002-3009; 2012

37. Zalzali H, Harajly M, Abdul-Latif L, El Chaar N, Dbaibo G, Skapek SX and Saab R. Temporally distinct roles for tumor suppressor pathways in cell cycle arrest and cellular senescence in Cyclin D1-driven tumor. Molecular Cancer, 11(1):28 [Epub ahead of print] (PMID: 22548705)

38. Widau RC, Zheng Y, Sung CY, Zelivianskaia A, Roach LE, Bachmeyer KM, Abramova T, Desgardin A, Rosner A, Cunningham JM, and Skapek SX. p19Arf controls platelet-derived growth factor receptor beta by transcriptional and post-transcriptional mechanisms. Molecular and Cellular Biology 32: 4270-4282; 2012

39. Hawkins DS, Spunt SL, and Skapek SX. Children’s Oncology Group’s 2013 blueprint for research: Soft tissue sarcomas. Pediatric Blood and Cancer 60: 1001-1008; 2013

40. Skapek SX, Anderson JR, Hill DA, Henry D, Spunt SL, Meyer W, Kao S, Hoffer FA, Grier HE, Hawkins DS, and Raney RB. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children’s Oncology Group (COG) Phase II study. Pediatric Blood and Cancer 60: 1108-1112; 2013

41. Skapek SX, Anderson J, Barr FG, Bridge JA, Gastier-Foster JM, Parham DM, Rudzinski ER, Triche T, and Hawkins SX. PAX-FOXO1 status drives unfavorable outcome for children with rhabdomyosarcoma: A Children’s Oncology Group report. Pediatric Blood and Cancer 60: 1411-1417; 2013

42. Khan MA, Liu J, Kumar G, Skapek SX, Falk JR, and Imig JD. Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB J. 27: 2946-2957; 2013

43. Zheng Y, Devitt C, Liu J, Mei J, and Skapek SX. A distant, cis-acting enhancer drives induction of Arf by Tgf in the developing eye. Developmental Biology 380: 49-57; 2013

44. Rudzinski ER, Teot LA, Anderson JR, Moore J, Bridge JA, Barr FG, Gastier-Foster JM, Skapek SX, Hawkins DS, and Parham DM. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: A report from the Soft Tissue Committee of the Children’s Oncology Group. American Journal of Clinical Pathology 140: 82-90; 2013

45. Lupo PJ, Zhou R, Skapek SX, Hawkins DS, Spector LG, Scheurer MD, Ocku FM, Melin B, Papworth K, Erhardt EB, and Grufferman S. Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: A report from the Children’s Oncology Group. International Journal of Cancer 134: 431-436; 2014

46. Wilson RA, Teng L, Bachmeyer KM, Bissonnette ML, Husain AN, Parham DM, Triche TJ, Wing MR, Gastier-Foster JM, Barr FG, Hawkins DS Anderson JR, Skapek SX*, Volchenboum SL*. A novel algorithm for simplification of complex gene classifiers in cancer. Cancer Research 73: 5625-5632; 2013 *corresponding authors

47. Zheng Y, Devitt C, Liu J, Iqbal, N, and Skapek SX. Arf induction by Tgf is influenced by Sp1 and C/ebp in opposing directions. PLoS One 2013 Aug 5;8(8):e70371.doi (Epub ahead of print)

48. Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, Spunt S, Valentine MB, Valentine V, Krafcik F, Lang WH, Wierdl M, Tsurkan L, Tolleman V, Federico SM, Morton C, Lu C, Ding L, Easton J, Rusch M, Nagahawatte P, Wang J, Parker M, Wei L, Hedlund E, Finkelstein D, Edmonson M, Shurtleff S, Boggs K, Mulder H, Yergeau D, Skapek S, Hawkins DS, Ramirez N, Potter PM, Sandoval JA, Davidoff AM, Mardis ER, Wilson RK, Zhang J, Downing JR, and Dyer MA. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 24: 710-724, 2013

49. Iqbal M, Mei J, Liu J, and Skapek SX. miR-34a is essential for p19Arf-driven cell cycle arrest. Cell Cycle 13: 792-800; 2014

50. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, and Khan J. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discovery 4: 216-231; 2014

51. Rudzinski ER, Anderson JR, Lyden ER, Bridge JA, Barr FG, Gastier-Foster JM, Bachmeyer K, Skapek SX, Hawkins DS, Teot LA, and Parham DM. Myogenin, AP2b, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: A report from the Children’s Oncology Group. Am J Surg Pathol 38: 654-659; 2014

52. Mary-Sinclair MBN, Wang XF, Swanson DJ, Sung C, Mendonca EA, Wroblewski K, Baumer SH, Goldowitz D, Jablonski MM, and Skapek SX. Varied manifestations of persistent hyperplastic primary vitreous with graded somatic mutation of a single gene. Molecular Vision 20: 215-230; 2014

53. Iqbal NS, Xu L, Devitt CC, and Skapek SX. Isolation and characterization of mammalian cells expressing the Arf promoter during eye development. Biotechniques 56: 239-249; 2014

54. Lupo PJ, Danysh HE, Skapek SX, Hawkins DS, Spector LG, Zhou R, Okcu MF, Papworth K, Erhardt EB, and Grufferman S. Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children’s Oncology Group. Cancer Causes Control 95: 905-913, 2015.

55. Kleiber GM, Skapek SX, Lingen M, and Reid RR. Odontogenic myxoma of the face: mimicry of cherubism. J Oral Maxillofac Surg 72: 2186-2191, 2014

56. Chen L, Shern JF, Wei JS, Yohe ME, Song YK, Hurd L, Liao H, Catchpoole D, Skapek SX, Barr FG, Hawkins DS, and Khan J. Clonality and evolutionary history of rhabdomyosarcoma. PLOS Genetics 2015 Mar 13;11(3):e1005075. doi: 10.1371/journal.pgen.1005075. eCollection 2015 Mar.

57. Lupo PJ, Danysh HE, Plon SE, Curtin K, Malkin D, Hettmer S, Hawkins DS, Skapek SX, Spector LG, Papworth K, Melin B, Erhardt EB, Grufferman S, Schiffman JD. Family history of cancer and childhood rhabdomyosarcoma: a report from the Children’s Oncology Group and the Utah Population Database. Cancer Med 4: 781-790, 2015.

58. Rudzinski ER, Anderson JR, Hawkins DS, Skapek SX, Parham DM, Teot LA. The World Health Organization classification of skeletal muscle tumors in pediatric rhabdomyosarcoma: a report from the Children’s Oncology Group. Arch Pathol Lab Med 139: 1281-1287, 2015.

59. Hingorani P, Missiaglia E, Shipley J, Anderson JR, Triche TJ, Delorenzi M, Gastier-Foster J, Wing M, Hawkins DS, and Skapek SX. Clinical application of a prognostic gene expression signature in fusion gene-negative rhabdomyosarcoma: a report from the Children’s Oncology Group. Clinical Cancer Research 21: 4733-4739, 2015.

60. Roy A, Kumar V, Zorman B, Fang E, Haines KM, Doddapaneni HV, Hampton OA, White S, Bavle AA, Patel NR, Eldin KW, Hicks JM, Rakheja D, Leavey PJ, Skapek SX, Amatruda JF, Nuchtern JG, Chintagumpala MM, Wheeler DA, Plon SA, Sumazin P, Parsons DW. Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. Nature Communications 6: 8891. Doi:1038/ncomms9891, 2015.

61. Arnold MA, Anderson JR, Gastier-Foster, JM, Barr RG, Skapek SX, Hawkins DS, Raney RB Jr, Parham DM, Teot LA, Rudzinski ER, Walterhouse DO. Histology, fusion status, and outcome in alveolar rhabdomyosarcoma with low-risk clinical features: A report from the Children’s Oncology Group. Pediatric Blood and Cancer 63: 634-639, 2016.

62. Iqbal NS, Devitt CC, Sung CY, Skapek SX. p19Arf limits primary vitreous cell proliferation driven by PDGF-B. Experimental Eye Research 145: 224-229, 2016.

63. Wilson RA, Liu J, Xu L, Annis J, Helmig S, Moore G, Timmerman C, Grandori C, Zheng Y, Skapek SX. Negative regulation of initial steps in skeletal myogenesis by mTOR and other kinases. Scientific Reports 6: 20376. doi: 10.1038/srep20376, 2016.

64. Sankaran H, Danysh HE, Sheurer ME, Okcu MF, Skapek SX, Hawkins DS, Spector LG, Erhardt EB, Grufferman S, Lupo PJ. The role of childhood infections and immunizations on childhood rhabdomyosarcoma: A report from the Children’s Oncology Group. Pediatric Blood and Cancer 63: 1557-1562, 2016.

65. Xu L, Wilson RA, Laetsch TW, Oliver D, Spunt SL, Hawkins DS, Skapek SX. Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children’s Oncology Group. Scientific Reports 6: 33429. doi: 10.1038/srep33429, 2016.

66. Rudzinski ER, Anderson JR, Chi YY, Gastier-Foster JM, Astbury C, Barr FG, Skapek SX, Hawkins DS, Weigel BJ, Pappo A, Meyer WH, Arnold MA, Teot LA, Parham DM. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children’s Oncology Group. Pediatric Blood and Cancer. 2017 May 18. doi: 10.1002/pbc.26645.

67. Teot LA, Schneider M, Thorner AR, Tian J, Chi Y-Y, Ducar M, Lin L, Wlodarski M, Grier HE, Fletcher CDM, van Hummelen P, Skapek SX, Hawkins DS, Wagers AJ, Rodriguez-Galindo C, Hettmer S. Clinical and mutational spectrum of highly differentiated, paired box3:forkhead box protein 01 fusion-negative rhabdomyosarcoma: A report from the Children’s Oncology Group. Cancer 124: 1973-1981, 2018.

68. Laetsch TW, Roy A, Xu L, Black JO, Coffin CM, Chi Y-Y, Tian J, Spunt SL, Hawkins DS, Bridge JA, Parsons DW, Skapek SX. Undifferentiated sarcomas in children harbor clinically relevant oncogenic fusions and gene copy-number alterations: A report from the Children’s Oncology Group. Clinical Cancer Research 24: 3888-3897, 2018.

69. Kendall GC, Watson S, Xu L, Murchison W, Rakheja D, Skapek SX, Tirode F, Delattre O, Amatruda JF. PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis. Elife. 2018 Jun 5;7. pii: e33800. doi: 10.7554/eLife.33800.

70. Xu L, Zheng Y, Liu J, Rakheja D, Singleterry S, Laetsch T, Shern JF, Khan J, Triche TJ, Hawkins DS, Amatruda JF, Skapek SX. Integrative Bayesian analysis identifies rhabdomyosarcoma disease genes. Cell Reports 24: 238-251, 2018.

71. Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clinical Oncology 36: 2770-2777, 2018.

72. Li S, Chen K, Zhang Y, Barnes SD, Jaichander P, Zheng Y, Hassan M, Malladi VS, Skapek SX, Xu L, Bassel-Duby R, Olson EN, Liu N. Twist2 amplification in rhabdomyosarcoma represses myogenesis and promotes oncogenesis by redirecting MyoD DNA binding. Genes and Development 33: 626-640, 2019.

73. Liu YT, Xu L, Bennett L, Hooks JC, Lu J, Zhou Q, Liem P, Zheng Y, Skapek SX. Identification of de novo enhancers activated by TGF to drive expression of CDKN2A and B in HeLa cells. Molecular Cancer Research 17: 1854-1866, 2019.

74. Hibbitts E, Chi YY, Hawkins DS, Barr FG, Bradley JA, Dasgupta R, Meyer WH, Rodeberg DA, Rudzinski ER, Spunt SL, Skapek SX, Wolden SL, Arndt CAS. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children’s Oncology Group. Cancer Medicine 2019 Aug 27. doi: 10.1002/cam4.2504. [Epub ahead of print].

75. Hassan M, Butler E, Wilson R, Roy A, Zheng Y, Liem P, Rakheja D, Pavlick D, Young L, Rozenzwieg M, Erlich R, Ali S, Leavey P, Parsons DW, Skapek SX, Laetsch TW. Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib. Molecular Case Studies 2019 (in press).

76. Sung CY, Liu YT, Bennett, LB, Devitt CC, Skapek SX. Testis-specific Arf promoter expression in a transposase-aided BAC transgenic mouse model. Molecular Biology Reports 2019 (in press).

Reviews, Chapters, Monographs and Editorials

1. Skapek SX, Ottolini MG. Dexamethasone therapy for bacterial meningitis (Letter to the Editor). N Engl J Med 320:463-464, 1989.

2. Lassar AB, Skapek SX, Novitch B. Regulatory mechanisms that coordinate skeletal muscle differentiation and cell cycle withdrawal. Curr Opin Cell Biol 6:788-794, 1994

3. Lin SJ, Skapek SX, Lee E. Genes in the RB pathway and their knockout in mice. Semin Cancer Biol 7:279-289, 1996.

4. Skapek SX, Qian Y-W, Lee E. The retinoblastoma protein: More than meets the eyes. Progress in Retinal and Eye Research 16:591-626, 1997.

5. Skapek SX, Shaffer LG, Barker JA. Cytogenetics and the biological basis of sarcomas. Current Opinion in Oncology 10:318-325, 1998.

6. Skapek SX and Chui CH. Cytogenetics and the biological basis of sarcomas. Current Opinion in Oncology 12: 315-322; 2000.

7. Kastan MB, and Skapek SX. Molecular biology of cancer: the cell cycle. In DeVita VT, Hellman S, and Rosenberg SA (Eds.), Cancer: Principles and Practice of Oncology (6th edition, pp. 91-109). Lippincott Williams and Wilkins (2001).

8. Spunt SL, Wolden SL, Schofield DE, and Skapek SX. Non-rhabdomyosarcoma soft tissue sarcomas. In Pappo AS (ed.), Pediatric Bone and soft tissue sarcomas (1st edition, pp. 133-162). Springer Verlag (2006).

9. Spunt SL, Skapek SX, and Coffin CM. Pediatric non-rhabdomyosarcoma soft tissue sarcomas. The Oncologist 13:668-78, 2008.

10. Huh W, Skapek SX. Childhood rhabdomyosarcoma: New insight on biology and treatment. Current Oncology Reports 12:402-10, 2010.

11. Weiss AR, Montag A, and Skapek SX. Desmoid tumor in children and adolescents: The influence of age. In Litchman C (Ed.) Desmoid tumors (1st edition, pp. 159-178). Springer (2011).

12. Saab RH, Spunt SL, and Skapek SX. Myogenesis and rhabdomyosarcoma: The Jekyll and Hyde of skeletal muscle. In Dyer MA (Ed.), Current Topics in Developmental Biology: Cancer and Development (Vol. 94, pp. 198-235). Elsevier (2011).

13. HaDuong JH, Martin AA, Skapek SX, and Mascarenhas L. Sarcomas. Pediatric Clinics of North America 62:179-200, 2015.

14. Wexler LH, Skapek SX, and Helman LJ. Rhabdomyosarcoma. In Pizzo PH and Poplack DG (Eds.) Principles and Practice of Pediatric Oncology (7th edition, pp. 798-826). Wolters Kluwer (2016).

15. Hingorani P, Janeway K, Crompton BD, Kadoch C, Mackall CL, Khan J, Shern JF, Schiffman J, Mirabello L, Savage SA, Ladanyi M, Meltzer P, Bult CJ, Adamson PC, Lupo PJ, Modey R, DuBois SG, Parson DW, Khanna C, Lau C, Hawkins DS, Randall RL, Smith M, Sorensen PH, Plon SE, Skapek SX, Lessnick S, Gorlick R, Reed DR. Current state of pediatric sarcoma biology and opportunities for future discover: A report from the sarcoma translational research workshop. Cancer Genetics 209: 182-194, 2016.

16. Skapek SX, Ferrari A, Gupta A, Lupo PJ, Butler E, Shipley J, Barr FG, and Hawkins DS. Rhabdomyosarcoma. Nature Reviews Disease Primers 2019; doi: 10.1038/s41572-018-0051-2.

Clinical Service

Inpatient
05/01/95 – 05/31/95 Pediatric Oncology Ward Attending, Children’s Hospital, Boston, Massachusetts
03/22/97 – 04/09/97 Pediatric Oncology Ward Attending, Wilford Hall Medical Center, San Antonio, Texas
08/09/97 – 08/24/97 Pediatric Oncology Ward Attending, Wilford Hall Medical Center, San Antonio, Texas
06/21/99 – 07/05/99 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
12/04/00 – 12/18/00 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
09/24/01 – 10/07/01 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
12/03/01 – 12/16/01 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
04/15/02 – 04/28/02 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
07/8/02 – 07/21/02 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
03/17/03 – 03/30/03 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
10/27/03 – 11/09/03 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
04/30/04 – 05/07/04 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
11/22/04 –12/05/04 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
11/21/05 –12/04/05 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
08/28/06 – 09/10/06 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
07/02/07 – 07/15/07 Solid Tumor Service Attending, St. Jude Children’s Research Hospital, Memphis, Tennessee
11/18/08 – 12/01/08 Hematology/Oncology Inpatient Attending, University of Chicago Comer Children’s Hospital, Chicago, Illinois
04/21/09 – 05/04/09 Hematology/Oncology Inpatient Attending, University of Chicago Comer Children’s Hospital, Chicago, Illinois
08/18/09 – 08/24/09 Hematology/Oncology Inpatient Attending, University of Chicago Comer Children’s Hospital, Chicago, Illinois
10/20/09 – 10/26/09 Hematology/Oncology Inpatient Attending, University of Chicago Comer Children’s Hospital, Chicago, Illinois
4/27/10 – 5/10/10 Hematology/Oncology Inpatient Attending, University of Chicago Comer Children’s Hospital, Chicago, Illinois
07/16/12 – 07/27/12 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
01/28/13 – 02/10/13 Oncology A Inpatient Attending, Children’s Medical Center, Dallas, Texas
07/29/13 – 08/04/13 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
08/25/14 – 08/31/14 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
12/08/14 – 12/14/14 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
04/27/15 – 05/3/15 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
06/15/15 – 06/20/15 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
08/26/15 – 08/30/15 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
11/30/15 – 12/05/15 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
02/15/16 – 02/19/16 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
04/02/16 – 04/03/16 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
06/06/16 – 06/12/16 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
05/08/17 – 05/14/17 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
07/31/17 – 08/06/17 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
06/02/18 – 06/03/18 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
07/02/18 – 07/06/18 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
01/12/19 – 01/18/19 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas
08/03/19 – 08/09/19 Oncology B Inpatient Attending, Children’s Medical Center, Dallas, Texas

Outpatient
7/1/00 – 9/15/07 Attending Physician, ½ day per week, Solid Tumor Clinic,
St. Jude Children’s Research Hospital, Memphis, Tennessee

2/1/08 – 07/31/11 Attending Physician, ½ day per week, Hematology/Oncology Clinic, Comer Children’s Hospital and the University of Chicago, Chicago, Illinois